unknown
Stage
2
Investors
About
Day One Biopharmaceuticals focuses on developing new medicines for children with pediatric low-grade glioma (pLGG) and provides resources to help families navigate diagnosis and treatment. The team includes experts in pediatric oncology, nursing, and drug development and aims to accelerate therapies for kids with pLGG.
Explore Day One Biopharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.